Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JASON B FLEMING and JEFFREY E LEE.
JASON B FLEMING
Connection Strength
2.334
JEFFREY E LEE
  1. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
    View in: PubMed
    Score: 0.126
  2. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015 Apr; 22(4):1168-75.
    View in: PubMed
    Score: 0.126
  3. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.120
  4. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S500-8.
    View in: PubMed
    Score: 0.112
  5. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012 Nov; 16(11):2056-63.
    View in: PubMed
    Score: 0.108
  6. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg. 2012 Aug; 215(2):e11-8.
    View in: PubMed
    Score: 0.108
  7. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012 Jul; 215(1):41-51; discussion 51-2.
    View in: PubMed
    Score: 0.106
  8. Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy. J Am Coll Surg. 2012 May; 214(5):778-87.
    View in: PubMed
    Score: 0.105
  9. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.102
  10. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol. 2011 Mar; 18(3):608-10.
    View in: PubMed
    Score: 0.097
  11. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg. 2009 Mar; 144(3):216-21.
    View in: PubMed
    Score: 0.085
  12. Screening for MEN1 mutations in patients with atypical endocrine neoplasia. Surgery. 1999 Dec; 126(6):1097-103; discussion 1103-4.
    View in: PubMed
    Score: 0.045
  13. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 1999 Nov; 230(5):697-707.
    View in: PubMed
    Score: 0.044
  14. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol. 2015 Oct; 39(10):1395-403.
    View in: PubMed
    Score: 0.033
  15. Rapid assessment of technical competency: the?8-min suture test. J Surg Res. 2016 Jan; 200(1):46-52.
    View in: PubMed
    Score: 0.033
  16. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.033
  17. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg. 2014 Jul; 219(1):111-20.
    View in: PubMed
    Score: 0.030
  18. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.029
  19. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med. 2013 Nov; 137(11):1619-26.
    View in: PubMed
    Score: 0.029
  20. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014 Jan; 18(1):146-55; discussion 155-6.
    View in: PubMed
    Score: 0.029
  21. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
    View in: PubMed
    Score: 0.029
  22. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology. 2013 Dec; 63(6):841-51.
    View in: PubMed
    Score: 0.029
  23. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol. 2013 Dec; 20(13):4073-9.
    View in: PubMed
    Score: 0.029
  24. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.029
  25. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB (Oxford). 2014 Apr; 16(4):373-83.
    View in: PubMed
    Score: 0.029
  26. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013 Jul; 20(7):2197-203.
    View in: PubMed
    Score: 0.028
  27. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Jun; 44(6):1024-30.
    View in: PubMed
    Score: 0.028
  28. Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology. 2013 Feb; 62(3):465-71.
    View in: PubMed
    Score: 0.027
  29. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol. 2012 Dec; 19(13):4078-84.
    View in: PubMed
    Score: 0.027
  30. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1336-43.
    View in: PubMed
    Score: 0.027
  31. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg. 2012 Jun; 147(6):513-9.
    View in: PubMed
    Score: 0.027
  32. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.027
  33. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.027
  34. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. HPB (Oxford). 2012 Aug; 14(8):506-13.
    View in: PubMed
    Score: 0.027
  35. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol. 2012 Apr; 36(4):552-9.
    View in: PubMed
    Score: 0.026
  36. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012 Mar; 36(3):409-17.
    View in: PubMed
    Score: 0.026
  37. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.026
  38. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.026
  39. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Aug 01; 118(15):3801-11.
    View in: PubMed
    Score: 0.026
  40. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012 Jan; 16(1):29-37.
    View in: PubMed
    Score: 0.026
  41. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012 Jun 15; 118(12):3182-90.
    View in: PubMed
    Score: 0.025
  42. Endoscopic management of duodenal adenomas in familial adenomatous polyposis--a single-center experience. Dig Dis Sci. 2012 Mar; 57(3):732-7.
    View in: PubMed
    Score: 0.025
  43. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Jan 01; 118(1):268-77.
    View in: PubMed
    Score: 0.025
  44. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
    View in: PubMed
    Score: 0.025
  45. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol. 2011 Dec; 18(13):3615-22.
    View in: PubMed
    Score: 0.025
  46. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010; 15(11):1205-13.
    View in: PubMed
    Score: 0.024
  47. Multidisciplinary management strategy for incidental cystic lesions of the pancreas. J Am Coll Surg. 2010 Aug; 211(2):205-15.
    View in: PubMed
    Score: 0.023
  48. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.023
  49. The fallen one: the inferior parathyroid gland that descends into the mediastinum. J Am Coll Surg. 2009 May; 208(5):887-93; discussion 893-5.
    View in: PubMed
    Score: 0.021
  50. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.021
  51. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008 Dec; 248(6):1098-102.
    View in: PubMed
    Score: 0.021
  52. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008 May; 206(5):833-46; discussion 846-8.
    View in: PubMed
    Score: 0.020
  53. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol. 1999 Jan-Feb; 16(1):50-63.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.